Inverna Therapeutics, an Argobio Studio co-founded spin-out from the University of Southern Denmark, is developing a novel RNA splicing modulation platform targeting pseudo-exons. Our technology offers a potential solution to limitations of current RNA therapeutics by enabling precise, sequence based and allele-specific targeting with minimal off-target effects
Inverna's platform has identified hundreds of thousands of potential pseudo-exon targets and is actively pursuing partnerships to advance its pipeline.
Company Details
- Employees
- 5
- Founded
- 2024
- Address
- Inverna Therapeutics Aps, Campusvej 55, Odense,denmark,5230,denmark
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.invernatx.com
- HQ
- Odense, Denmark
Inverna Therapeutics Questions
Inverna Therapeutics's website is https://www.invernatx.com
Inverna Therapeutics's LinkedIn profile is https://dk.linkedin.com/company/inverna-tx
Inverna Therapeutics has
5 employees.
View email and phone details for 5
employees at Inverna Therapeutics.
Inverna Therapeutics's industry is
Biotechnology Research
Inverna Therapeutics's top competitors are
Laigo Bio,
Elkedonia,
Glyprovac,
Argobio Studio,
Enodia Therapeutics,
Cenexum,
Vertanical,
Acesion Pharma,
Crucible Therapeutics,
Orifarm.
Inverna Therapeutics's categories are Biotechnology Research
Inverna Therapeutics's founding year is 2024
